NCT06151236View on ClinicalTrials.gov

Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 11, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

April 30, 2034

Conditions
Merkel Cell Carcinoma
Interventions
DRUG

Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination

Dual inhibition of the distinct LAG3 and PD-1 checkpoint pathways

Trial Locations (2)

2065

RECRUITING

Melanoma Institute Australia, Wollstonecraft

RECRUITING

Melanoma Institute Australia, Wollstonecraft

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Melanoma Institute Australia

OTHER